Martha Morrell Sells 78,334 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the sale, the insider now owns 81,993 shares in the company, valued at $1,124,943.96. This trade represents a 48.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The stock was sold at an average price of $15.00, for a total transaction of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The stock was sold at an average price of $15.01, for a total value of $48,032.00.

NeuroPace Trading Down 2.6 %

NPCE opened at $13.48 on Thursday. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $17.37. The business’s 50 day moving average is $12.63 and its two-hundred day moving average is $9.58. The firm has a market cap of $402.35 million, a price-to-earnings ratio of -13.48 and a beta of 2.05.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in NeuroPace during the 4th quarter valued at approximately $29,000. Wells Fargo & Company MN raised its stake in shares of NeuroPace by 54.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock worth $73,000 after purchasing an additional 2,279 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of NeuroPace during the fourth quarter worth $103,000. Cubist Systematic Strategies LLC purchased a new position in NeuroPace in the 4th quarter valued at $112,000. Finally, Birchview Capital LP purchased a new stake in shares of NeuroPace in the fourth quarter valued at about $112,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on NPCE. UBS Group initiated coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company raised their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, NeuroPace has an average rating of “Moderate Buy” and an average target price of $14.80.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.